Two TAAR1 agonists, Ulotaront (Sunovion) and Ralmitaront (Hoffmann–La Roche), already advanced into clinical trials for the treatment of several conditions including narcolepsy (20), psychosis in Parkinson’s disease (21, 22), and schizophrenia (23). Here, TAAR1 is linked to Parkinson disease.